787.F SELVITA S.A. SER.B ZY-80

Healthcare Biotechnology Frankfurt Exchange
3.64 EUR
Close of Nov 11, 2026
3.50 11.05
Market cap
EUR 66.9M
P/E
-
P/B
0.93x
ROE
-5.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 787.F undervalued?

Graham number

The Graham number of SELVITA S.A. SER.B ZY-80 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

SELVITA S.A. SER.B ZY-80 fundamental analysis

No fundamental analysis for SELVITA S.A. SER.B ZY-80 yet.

SELVITA S.A. SER.B ZY-80 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About SELVITA S.A. SER.B ZY-80

Selvita S.A. provides drug discovery, drug development, and contract testing services in Poland. The company offers computer-aided drug design and artificial intelligence solutions, including structure-based drug design, virtual screening, and bioinformatics; medicinal and synthetic, analytical, and solid state chemistry, as well as process chemistry and scale up, and compound management and libraries; structural biology, fragment-based drug discovery, protein production, mo…

Full company profile